<DOC>
	<DOCNO>NCT02376010</DOCNO>
	<brief_summary>Current oral anti-coagulation atrial fibrillation commonly perform warfarin . Warfarin vitamin K antagonist show non-randomized trial increase vascular calcification . Increased vascular calcification tie increase cardiovascular event ( CVE ) . This study randomize patient currently take warfarin either continue warfarin switch rivaroxaban . Rivaroxaban oral anti-coagulant work inhibit Factor Xa , interaction vitamin K. This study randomize , open label study randomize 120 patient undergo blood test calcium scan baseline , 12 month . Patients see quarterly examination , safety check supply rivaroxaban , well follow INR test warfarin .</brief_summary>
	<brief_title>Rivaroxaban Versus Warfarin Evaluation Progression Coronary Calcium</brief_title>
	<detailed_description>Rivaroxaban novel oral direct factor Xa inhibitor show reduce risk stroke similar population comparison warfarin . The rate myocardial infarction 9 % low rivaroxaban group warfarin group Rocket AF study similarly myocardial infarction rate 12 % low apixaban group Aristotle , difference significant either trial . The potential long term benefit avoid VKA therapy may much great CV event reduction . The study propose evaluate marker CAC progression atherosclerosis development , long term outcome data support slowing process associate low CV event .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Key 1 . Eligible patient atrial fibrillation enrollment two episode atrial fibrillation flutter , document electrocardiography , least 2 week apart 12 month enrollment 2 . Age 1884 3 . On Warfarin 6 month prior enrollment stable dose . 4 . Willingness participate study ability sign inform consent 5 . Minimum CAC score 10 Key 1 . Atrial fibrillation due reversible cause , moderate severe mitral stenosis , condition atrial fibrillation require anticoagulation ( e.g. , prosthetic heart valve ) 2 . Prior apixaban , dabigatran , rivaroxaban use . 3 . A need aspirin dose &gt; 165 mg day aspirin clopidogrel , 4 . Renal insufficiency ( serum creatinine level 12.5 mg per deciliter calculate creatinine clearance &lt; 50 ml per minute ) . 5 . Serious bleed event previous 6 month high risk bleeding ( eg , active peptic ulcer disease , platelet count &lt; 100,000/mm3 hemoglobin level &lt; 10 g/dL , stroke within previous 10 day , document hemorrhagic tendency , blood dyscrasia ) 6 . Weight excess 325 pound 7 . Resting hypotension ( systolic blood pressure &lt; 90mmHg ) rest hypertension ( systolic blood pressure &gt; 170mmHg diastolic blood pressure &gt; 110 mmHg ) . 8 . History active malignancy require concurrent chemotherapy . 9 . Any unstable medical , psychiatric , substance abuse disorder opinion principal investigator likely affect subject 's ability complete study . 10 . Known allergy iodinate contrast material 11 . Pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>atherosclerosis</keyword>
	<keyword>coronary artery disease</keyword>
	<keyword>cardiac CT</keyword>
	<keyword>compute tomographic angiography</keyword>
</DOC>